Influenza Vaccine Composition for the 2015-2016 Season

US-licensed trivalent influenza vaccines will contain hemagglutinin (HA) derived from an A/California/7/2009 (H1N1)-like virus, an A/Switzerland/9715293/2013 (H3N2)-like virus, and a B/Phuket/3073/2013-like (Yamagata lineage) virus. This represents changes in the influenza A (H3N2) virus and the influenza B virus as compared with the 2014–2015 season.

New Vaccine Product Approvals

Several new products are being debuted this coming season.

  • Afluria (inactivated influenza vaccine; bioCSL) for intramuscular administration via the Stratis needle-free jet injector, for persons aged 18–64 years: while either the injector or the more traditional sterile needle and syringe may also be used for this product, all other inactivated influenza vaccines should be administered by sterile needle and syringe only.
  • An expanded age indication for the use of Flublok (recombinant influenza vaccine, trivalent [RIV3]; Protein Sciences Corporation), which was previously approved only for persons aged 18–49 years: Flublok is now indicated for individuals age ≥50 as well.
  • Fluzone Intradermal Quadrivalent is anticipated to replace the previously available trivalent Fluzone Intradermal (Sanofi Pasteur).